LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh...
The marketing approval of Enstilar(R) would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received...
Not Intended for US Media LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the...
LEO Pharma announces a co-creation agreement with the National Psoriasis Foundation (NPF) in the United States that puts patients at the heart of LEO Pharma's innovation process. The move supports the dermatology company's aim to develop future care...
Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now...
LEO Pharma A/S, a global pharmaceutical company specialising in dermatology, has entered into an exclusive research and license agreement with the German biotech company 4SC Discovery GmbH with the primary aim of jointly...
Psoriasis is a little-understood skin condition that carries a strong social stigma through its emotional impact on sufferers that can far outweigh the disease's physical impact. That is why...
Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is...
LEO Pharma has announced plans to establish five long-term, strategic research collaborations in four countries by the end of next year. The ambitious initiative aims to deliver new treatment options to dermatology patients –faster than ever...
- LEO Pharma has conducted the first truly large scale international study informed by both qualitative and quantitative data to investigate the impact of psoriasis - The...
LEO Pharma is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline. Corporate VP hopes to sign two or more new deals before the end of 2012. (Logo: http://photos...